MTX-211

MTX-211 is a first-in-class, dual-acting small molecule inhibitor that selectively targets both the Epidermal Growth Factor Receptor (EGFR) and Phosphoinositide 3-kinase (PI3K). Developed by Mekanistic Therapeutics, the compound is designed to address adaptive signaling mechanisms and resistance pathways in KRAS-mutant cancers. Preclinical studies have demonstrated that MTX-211 can significantly potentiate the activity of MEK inhibitors, such as trametinib, by suppressing the compensatory transcriptional activation of HER3 that often occurs in response to MAPK pathway inhibition. It has shown promising efficacy in animal models and patient-derived xenografts of pancreatic and colorectal cancers.